Tomoki Naoe

List of Publications by Year in Descending Order

160 papers	16,159 citations	58 h-index	126 g-index
166 ext. papers	18,595 ext. citations	4.8 avg, IF	6 L-index

#	Paper	IF	Citations
160	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. *HemaSphere*, **2021**, 5, e617	0.3	1
159	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. *Blood Advances*, **2020**, 4, 66-75	7.8	22
158	Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. *Cancer Science*, **2020**, 111, 2472-2481	6.9	1
157	Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. *Cancers*, **2020**, 12,	6.6	2
156	<EditorsCChoice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. *Nagoya Journal of Medical Science*, **2020**, 82, 151-160	0.7	1
155	Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. *Annals of Hematology*, **2020**, 99, 2787-2800	3	4
154	ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities. *FEBS Letters*, **2019**, 593, 2151-2161	3.8	3
153	Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. *Blood*, **2019**, 133, 1630-1643	2.2	219
152	Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. *International Journal of Hematology*, **2019**, 109, 418-425	2.3	3
151	Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. *Leukemia*, **2019**, 33, 358-370	10.7	14
150	Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity. *Oncogene*, **2019**, 38, 2263-2274	9.2	11
149	Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. *Annals of Hematology*, **2019**, 98, 83-91	3	16
148	Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography. *Scientific Reports*, **2018**, 8, 4008	4.9	5
147	Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. *Leukemia Research*, **2018**, 66, 20-27	2.7	31
146	Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. *Leukemia Research*, **2018**, 65, 34-41	2.7	1
145	Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. *Annals of Hematology*, **2018**, 97, 1535-1545	3	22
144	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. *International Journal of Hematology*, **2018**, 107, 201-210	2.3	12

143	Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. *Supportive Care in Cancer*, **2018**, 26, 4187-4198	3.9	10
142	A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with mutations. *Blood*, **2018**, 131, 426-438	2.2	64
141	Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. *Annals of Hematology*, **2018**, 97, 73-81	3	8
140	Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia. *Haematologica*, **2018**, 103, e522-e526	6.6	10
139	Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. *American Journal of Hematology*, **2017**, 92, 367-374	7.1	8
138	Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. *Cancer Science*, **2017**, 108, 1628-1633	6.9	37
137	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*, **2017**, 129, 424-447	2.2	2764
136	Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. *Cancer Science*, **2016**, 107, 1422-1429	6.9	85
135	SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. *Cancer Science*, **2016**, 107, 1270-80	6.9	15
134	Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. *Nature Genetics*, **2016**, 48, 569-74	36.3	141
133	Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. *Oncotarget*, **2016**, 7, 47018-47032	3.3	24
132	Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission. *European Journal of Haematology* , **2016**, 97, 278-87	3.8	10
131	Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. *Cancer Science*, **2015**, 106, 896-901	6.9	64
130	Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia. *Cancer Science*, **2015**, 106, 1590-5	6.9	29
129	Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. *Journal of Immunology*, **2015**, 194, 911-20	5.3	150
128	Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2014**, 1843, 590-602	4.9	33
127	Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. *Cancer Science*, **2014**, 105, 97-104	6.9	22
126	Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. *Journal of Clinical Oncology*, **2014**, 32, 3729-35	2.2	40

125	Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2014**, 1839, 1256-72	6	115
124	De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. *Cancer Science*, **2014**, 105, 35-43	6.9	14
123	Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk. *PLoS ONE*, **2014**, 9, e92861	3.7	18
122	Tamibarotene for the treatment of acute promyelocytic leukemia. *Expert Opinion on Orphan Drugs*, **2014**, 2, 961-969	1.1	1
121	DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2013**, 1829, 1102-10	6	45
120	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. *Blood*, **2013**, 121, 3095-102	2.2	58
119	CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). *Leukemia Research*, **2013**, 37, 1021-6	2.7	30
118	Gene mutations of acute myeloid leukemia in the genome era. *International Journal of Hematology*, **2013**, 97, 165-74	2.3	48
117	Tumor-suppressive microRNA-145 targets catenin 1 to regulate Wnt/ catenin signaling in human colon cancer cells. *Cancer Letters*, **2013**, 335, 332-42	9.9	68
116	Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. *Molecular Therapy*, **2013**, 21, 1204-11	11.7	47
115	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. *International Journal of Hematology*, **2013**, 97, 717-25	2.3	126
114	The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies. *Cancer*, **2013**, 119, 3326-33	6.4	9
113	Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. *Cancer Science*, **2013**, 104, 1339-45	6.9	11
112	CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. *Experimental Hematology*, **2012**, 40, 724-737.e2	3.1	17
111	Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study. *International Journal of Hematology*, **2012**, 96, 485-91	2.3	5
110	Acute myeloid leukemia in older adults. *International Journal of Hematology*, **2012**, 96, 186-93	2.3	45
109	Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis. *International Journal of Hematology*, **2012**, 96, 295-300	2.3	20
108	Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. *International Journal of Hematology*, **2012**, 95, 409-19	2.3	15

107	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study. *International Journal of Hematology*, **2012**, 96, 84-93	2.3	27
106	A Phase III Study of New Synthetic Retinoid Tamibarotene(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study. *Blood*, **2012**, 120, 410-410	2.2	3
105	Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. *Blood*, **2011**, 117, 2358-65	2.2	174
104	Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. *American Journal of Pathology*, **2011**, 179, 1088-94	5.8	38
103	MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. *Cancer Letters*, **2011**, 307, 211-20	9.9	114
102	Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. *Blood*, **2011**, 118, 1600-9	2.2	84
101	Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. *Haematologica*, **2011**, 96, 174-6	6.6	12
100	Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study. *Cancer Science*, **2011**, 102, 1358-65	6.9	4
99	FLT3/ ITD regulates leukaemia cell adhesion through 41 integrin and Pyk2 signalling. *European Journal of Haematology*, **2011**, 86, 191-8	3.8	12
98	Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. *International Journal of Hematology*, **2011**, 93, 66-73	2.3	26
97	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. *International Journal of Hematology*, **2011**, 93, 237-242	2.3	11
96	A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. *Blood*, **2011**, 117, 2366-72	2.2	125
95	Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. *Leukemia Research*, **2011**, 35, 685-8	2.7	8
94	Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. *Molecular Therapy*, **2011**, 19, 395-9	11.7	194
93	Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. *Cancer Science*, **2010**, 101, 1480-6	6.9	83
92	Identification of non-coding RNAs embracing microRNA-143/145 cluster. *Molecular Cancer*, **2010**, 9, 136	42.1	67
91	Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. *American Journal of Pathology*, **2010**, 177, 547-54	5.8	98
90	Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. *Leukemia and Lymphoma*, **2010**, 51, 1855-61	1.9	30

89	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood*, **2010**, 115, 453-74	2.2	2483
88	Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study. *International Journal of Hematology*, **2010**, 91, 276-83	2.3	23
87	BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4. *European Journal of Haematology*, **2010**, 84, 229-38	3.8	26
86	Decreased expression of microRNA-143 and -145 in human gastric cancers. *Oncology*, **2009**, 77, 12-21	3.6	244
85	Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. *European Journal of Haematology*, **2009**, 83, 90-8	3.8	38
84	Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *International Journal of Hematology*, **2009**, 89, 3-13	2.3	23
83	Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. *Leukemia Research*, **2009**, 33, 1530-8	2.7	74
82	Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. *Biochemical and Biophysical Research Communications*, **2009**, 390, 48-53	3.4	34
81	Presentation and management of intravascular large B-cell lymphoma. *Lancet Oncology, The*, **2009**, 10, 895-902	21.7	210
80	Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. *Blood*, **2009**, 113, 1875-91	2.2	720
79	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. *Blood*, **2009**, 113, 4885-93	2.2	177
78	KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. *Blood*, **2009**, 114, 1607-17	2.2	98
77	Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome. *British Journal of Haematology*, **2008**, 140, 394-401	4.5	38
76	Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. *British Journal of Haematology*, **2008**, 143, 503-10	4.5	71
75	Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. *European Journal of Haematology*, **2008**, 81, 454-60	3.8	18
74	Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. *Leukemia and Lymphoma*, **2008**, 49, 2359-64	1.9	5
73	Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. *Journal of Clinical Oncology*, **2008**, 26, 3189-95	2.2	192
72	BCR-ABL-transformed GMP as myeloid leukemic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 17967-72	11.5	76

71	Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. *Haematologica*, **2008**, 93, 287-90	6.6	47
70	Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol. *International Journal of Hematology*, **2008**, 87, 144-151	2.3	17
69	Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. *International Journal of Hematology*, **2008**, 88, 149-153	2.3	29
68	Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5472-7	2.9	10
67	Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma. *Journal of Clinical and Experimental Hematopathology: JCEH*, **2008**, 48, 25-8	1.9	11
66	Retention but Significant Reduction of BCR-ABL Transcript in Hematopoietic Stem Cells in Chronic Myelogenous Leukemia after Imatinib Therapy.. *Blood*, **2008**, 112, 2116-2116	2.2	
65	Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 5620-8	3.4	136
64	Downregulation of microRNAs-143 and -145 in B-cell malignancies. *Cancer Science*, **2007**, 98, 1914-20	6.9	250
63	Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. *European Journal of Haematology*, **2007**, 78, 213-9	3.8	100
62	Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. *International Journal of Hematology*, **2007**, 86, 49-57	2.3	39
61	A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations. *Clinical Cancer Research*, **2007**, 13, 4575-82	12.9	29
60	Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. *Clinical Cancer Research*, **2007**, 13, 5124-32	12.9	347
59	A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. *Blood*, **2007**, 110, 59-66	2.2	134
58	A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. *Transplantation*, **2007**, 83, 1242-8	1.8	27
57	MicroRNA-143 and -145 in colon cancer. *DNA and Cell Biology*, **2007**, 26, 311-20	3.6	188
56	Acetylation of PML Plays a Key Role in Histone Deacetylase Inhibitor-Mediated Apoptosis through Enhanced PML Sumoylation.. *Blood*, **2007**, 110, 4164-4164	2.2	
55	Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. *Cancer Genetics and Cytogenetics*, **2006**, 169, 1-11		12
54	Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies. *Current Pharmaceutical Biotechnology*, **2006**, 7, 331-7	2.6	2

53	High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. *Journal of Clinical Oncology*, **2006**, 24, 460-6	2.2	354
52	Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. *Leukemia and Lymphoma*, **2006**, 47, 1747-53	1.9	30
51	Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. *Biochemical and Biophysical Research Communications*, **2006**, 345, 1471-80	3.4	41
50	let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. *Biological and Pharmaceutical Bulletin*, **2006**, 29, 903-6	2.3	525
49	Nucleophosmin: a versatile molecule associated with hematological malignancies. *Cancer Science*, **2006**, 97, 963-9	6.9	59
48	SFK-STAT pathway: an alternative and important way to malignancies. *Annals of the New York Academy of Sciences*, **2006**, 1086, 213-22	6.5	22
47	Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. *International Journal of Hematology*, **2006**, 84, 328-36	2.3	5
46	Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. *International Journal of Hematology*, **2006**, 83, 301-8	2.3	46
45	FLT3 mutations in acute myeloid leukemia. *Methods in Molecular Medicine*, **2006**, 125, 189-97		11
44	MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. *Oncology Reports*, **2006**, 16, 845-50	3.5	203
43	Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. *Blood*, **2005**, 106, 2854-61	2.2	225
42	BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. *International Journal of Hematology*, **2005**, 82, 42-7	2.3	69
41	Long-term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single-center experience. *European Journal of Haematology*, **2005**, 74, 418-23	3.8	31
40	Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. *Cancer*, **2005**, 103, 1652-8	6.4	141
39	Integrin activation and matrix binding mediate cellular responses to mechanical stretch. *Journal of Biological Chemistry*, **2005**, 280, 16546-9	5.4	181
38	Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway. *Leukemia and Lymphoma*, **2004**, 45, 987-95	1.9	17
37	Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. *Biochemical and Biophysical Research Communications*, **2004**, 320, 920-6	3.4	15
36	Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. *Blood*, **2004**, 104, 3507-12	2.2	150

35	Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. *Blood*, **2004**, 103, 1901-8	2.2	214
34	Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. *Blood*, **2003**, 102, 2969-75	2.2	73
33	A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. *Cancer Genetics and Cytogenetics*, **2003**, 144, 31-5		8
32	Antitumor effect of arsenic trioxide in murine xenograft model. *Cancer Science*, **2003**, 94, 1010-4	6.9	35
31	Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation. *Oncogene*, **2003**, 22, 9176-84	9.2	83
30	Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. *Journal of Experimental Medicine*, **2003**, 197, 1489-500	16.6	128
29	Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. *Oncogene*, **2002**, 21, 2555-63	9.2	220
28	Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. *Life Sciences*, **2002**, 70, 2253-69	6.8	82
27	FLT3 in human hematologic malignancies. *Leukemia and Lymphoma*, **2002**, 43, 1541-7	1.9	59
26	FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. *Cancer Chemotherapy and Pharmacology*, **2001**, 48 Suppl 1, S27-30	3.5	33
25	B-cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony-stimulating factor-mobilized peripheral blood CD34+ cells. *Immunology*, **2001**, 104, 410-7	7.8	25
24	Novel heterozygous missense mutation in the platelet glycoprotein Ib beta gene associated with isolated giant platelet disorder. *American Journal of Hematology*, **2001**, 68, 249-55	7.1	32
23	In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice. *Japanese Journal of Cancer Research*, **2001**, 92, 529-36		52
22	Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. *Japanese Journal of Cancer Research*, **2001**, 92, 638-44		77
21	Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. *British Journal of Haematology*, **2000**, 108, 696-702	4.5	75
20	Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. *Oncogene*, **2000**, 19, 624-31	9.2	451
19	Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. *Japanese Journal of Cancer Research*, **2000**, 91, 1154-60		35
18	Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. *Leukemia Research*, **2000**, 24, 349-52	2.7	24

17	Leukemia relapse reconsidered from the molecular aspect. *Leukemia and Lymphoma*, **2000**, 37, 527-34	1.9	1
16	Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. *British Journal of Haematology*, **1999**, 104, 659-64	4.5	92
15	A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. *Cancer Genetics and Cytogenetics*, **1998**, 100, 21-4		18
14	Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study. *British Journal of Haematology*, **1998**, 100, 383-6	4.5	24
13	Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. *British Journal of Haematology*, **1998**, 101, 521-8	4.5	64
12	Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. *British Journal of Haematology*, **1998**, 102, 1055-60	4.5	125
11	Immunoaffinity purification and characterization of CACGTG sequence-binding proteins from cultured mammalian cells using an anti c-Myc monoclonal antibody recognizing the DNA-binding domain. *Journal of Biochemistry*, **1997**, 121, 550-9	3.1	7
10	Treatment With a New Synthetic Retinoid, Am80, of Acute Promyelocytic Leukemia Relapsed From Complete Remission Induced by All-trans Retinoic Acid. *Blood*, **1997**, 90, 967-973	2.2	162
9	Increased but highly dispersed levels of plasma glycocalicin in patients with disseminated intravascular coagulation. *European Journal of Haematology*, **1996**, 56, 173-7	3.8	6
8	Molecular cloning of the breakpoint of t(11;22) (q23;q11) chromosome translocation in an adult acute myelomonocytic leukaemia. *British Journal of Haematology*, **1996**, 92, 687-91	4.5	9
7	Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: sequence non-specific recombination between the PML and RARA genes within identical short stretches. *Genes Chromosomes and Cancer*, **1995**, 12, 37-44	5	32
6	Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. *Cancer*, **1993**, 71, 3888-95	6.4	87
5	Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. *Japanese Journal of Cancer Research*, **1993**, 84, 379-87		32
4	Molecular heterogeneity of the PML gene rearrangement in acute promyelocytic leukemia: prevalence and clinical significance. *Japanese Journal of Cancer Research*, **1993**, 84, 257-64		14
3	Diversity of cellular molecules in human cells detected by monoclonal antibodies reactive with c-myc proteins produced in Escherichia coli. *Japanese Journal of Cancer Research*, **1989**, 80, 747-53		13
2	Production of a truncated human c-myc protein which binds to DNA. *FEBS Letters*, **1988**, 240, 49-54	3.8	3
1	Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. *Cancer Genetics and Cytogenetics*, **1988**, 34, 77-88		20